|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, clear evidence for regulating miRNA processing and VEGF output by intrinsic PGE-2 production provides a means to distinguish between aggressive and indolent prostate tumors and suggests a potential target for controlling tumor progression.
|
27322147 |
2016 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These inhibitory effects were accompanied by mechanistic down-regulation of the protein levels of inflammatory enzymes (inducible nitric oxide synthase, iNOS and cyclooxygenase-2, COX-2), metastasis (matrix metallopeptidase-2, MMP-2 and MMP-9), angiogenesis (vascular endothelial growth factor, VEGF), and proliferative molecules, as well as by the induction of apoptosis in prostate tumors.
|
23673480 |
2013 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
One study in nude mice injected via tail vein with hepatocarcinoma SK-Hep-1 cells showed that BC decreases the plasma VEGF level, whereas the other study in nude mice injected subcutaneously with prostate tumor PC-3 cells showed that BC increases the plasma VEGF level.
|
22469593 |
2012 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
|
20052738 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer.
|
19089921 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Nevirapine induced extensive reprogramming of gene expression in vitro with up-regulation of genes that might be silenced during prostate tumor progression (i.e., K18, PSA and androgen receptor) and down-regulation of genes involved in the progression toward an androgen-independent phenotype (i.e., K5, EGFR1, EGF and VEGF-A).
|
19152342 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway.
|
18615482 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A statistically significant correlation between expression of cyclin A1 and of MMP2, MMP9, and VEGF was observed in prostate tumors from 482 patients (P values from Spearman rank correlation tests < .001).
|
18612129 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
|
18437586 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.
|
18240292 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
|
18486981 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Prostate tumors showed a significant increase in the percentage of VEGF(121) and decreases in VEGF(165) (p < 0.01) and VEGF(189) (p < 0.05).
|
17278099 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These observations support the hypothesis that genistein may inhibit prostate tumor angiogenesis through the suppression of VEGF-mediated autocrine and paracrine signaling pathways between tumor cells and vascular endothelial cells.
|
17142033 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
|
17549360 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin 8 (IL-8) and vascular endothelial growth factor (VEGF) are two cytokines promoting prostate tumor growth and angiogenesis.
|
16530725 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome.
|
16908180 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression.
|
16606632 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
|
16820871 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells.
|
16826426 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.
|
16278385 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Vascular endothelial growth factor (VEGF), its receptors (VEGFRs), and alpha5beta1 integrin were expressed by prostate cancer cells in vitro and by prostate tumors in vivo, and their expression was elevated at sites of bone metastasis compared to original prostate tumor.
|
15500293 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF), its receptors (VEGFRs), and alpha5beta1 integrin were expressed by prostate cancer cells in vitro and by prostate tumors in vivo, and their expression was elevated at sites of bone metastasis compared to original prostate tumor.
|
15500293 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
|
15701844 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
|
15905202 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.
|
16007189 |
2005 |